Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck & Co., Inc
Woman Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Phase IIa Open Label, Randomized Clinical Trial to Study Vintafolide and Paclitaxel in Subjects with Advanced Triple Negative Breast Cancer Using SPECT/CT scan with Etarfolatide (EC20) for Subject Selection Ensayo clínico de fase IIa abierto y aleatorizado para estudiar Vintafolide y paclitaxel en pacientes con cáncer de mama triplemente negativo avanzado, con selección de pacientes mediante etarfolatide (EC20)
To evaluate the progression-free survival of vintafolide monotherapy relative to paclitaxel and the progression-free survival of vintafolide + paclitaxel combination therapy relative to paclitaxel in...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 5 ans
Study of CANCIDAS in Children types of ungal infections
The main objectives of this study are to evaluate the safety, tolerability, and efficacy of caspofungin therapy, administered as 50 mg/m2 IV once daily (maximum 70 mg/day) following a loading dose of ...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A Phase III, Randomized, Double-blind Study to Evaluate Chemotherapy plus Pembrolizumab vs Chemotherapy plus Placebo as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
1. To evaluate the rate of pCR using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) as assessed by the local pathologist at the ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A clinical research study to test the safety/tolerability and effectiveness of an investigational study medication (subcutaneous SCH 900222/MK-3222) in improving the signs and symptoms of moderate-to-severe chronic plaque psoriasis, and to compare it to an approved medication for the treatment of psoriasis called etanercept
Primary Efficacy Objective: To assess the efficacy of SCH 900222/MK-3222, hereafter referred to as MK-3222, compared to placebo in the treatment of moderate-to-severe chronic plaque psoriasis as measu...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Oral MK8669 in Children/Adolescents with Solid Tumors (6-17 years)
• To identify the dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of ridaforolimus when administered to children from 6 to less than 18 years of age with advanced solid tumours. • To...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A Study of Boceprevir in Patients who have HIV and Hepatitis C
The primary objective of this study is to compare the efficacy of boceprevir (PO) in combination with peginterferon alfa-2b (PEG2b) (SC) plus ribavirin weight-based dosing (WBD) PO to therapy with PEG...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Extended-Release (ER) Niacin and Laropiprant (ERN/LRPT) in Patients with Dyslipidemia
Main objective: Assess the effects of ERN/LRPT relative to ERN on flushing during the post-withdrawal dosing period as measured by number of days/week with GFSS >4 during weeks 21 to 32.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
sitagliptin +simvastatin coadministration safety study sitagliptin és simvastatin egyidejű alkalmazásának biztonságossági vizsgálata
1. To assess the effect of MK-0431D compared to sitagliptin alone on A1C. 2. To assess the safety and tolerability of MK-0431D.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Phase III study of carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) with or without pembrolizumab in first line metastatic squamous NSCLC. Estudio de fase III de carboplatino y paclitaxel o paclitaxel unido a albúmina en nanopartículas (nab-paclitaxel), con o sin pembrolizumab, en el CPNM epidermoide y metastásico en primera línea de tratamiento
In subjects with metastatic squamous non-small cell lung cancer (NSCLC) receiving investigator’s choice of standard of care chemotherapy (i.e. carboplatin and a taxane): 1. To evaluate progression fre...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 5 ans
A Two Year Study to Assess the Efficacy, Safety, and Tolerability of MK-0364 in Obese Patients Followed by a 1-Year Extension
In obese patients, (1) to assess the effects of 2 or 4 mg MK-0364 after 1 year of treatment on body weight; (2) to assess the safety and tolerability of MK-0364 during base and extension studies.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
2
3
4
5
6
7
8
9
10
11
Next